Hua Bai1, Danqing Jing, Aitao Guo, Shinan Yin. 1. Department of Endocrinology, First Affiliated Hospital of The General Hospital of the People's Liberation Army (PLA), Beijing 100048, China.
Abstract
OBJECTIVE: To assess the effect of zoledronic acid (ZOL) on bone mineral density (BMD) and fracture risk at the L1-L4 vertebrae, femoral neck, hip and trochanter in Chinese women with osteoporosis. METHODS: A randomized controlled trial was conducted in female patients with osteoporosis, randomized to receive one 5-mg ZOL intravenous infusion per year or placebo equivalent. Facture risk and BMD were measured over a 2-year follow-up period. RESULTS: A statistically significant reduction in the risk of fracture was observed at the trochanter in the ZOL group (n = 242) compared with the placebo group (n = 241); (odds ratio 0.54 [95% confidence interval 0.29, 0.98]): BMD was 0.24, 0.28, 0.31 and 0.22 greater at the L1-L4 vertebrae, total hip, femoral neck and trochanter, respectively, in the ZOL group. The incidence of adverse events was comparable between treatment groups. CONCLUSIONS: This study indicated that ZOL could increase BMD and reduce fracture risk in women with osteoporosis over a 2-year follow-up period, and was not associated with any serious drug-related adverse effects.
RCT Entities:
OBJECTIVE: To assess the effect of zoledronic acid (ZOL) on bone mineral density (BMD) and fracture risk at the L1-L4 vertebrae, femoral neck, hip and trochanter in Chinese women with osteoporosis. METHODS: A randomized controlled trial was conducted in female patients with osteoporosis, randomized to receive one 5-mg ZOL intravenous infusion per year or placebo equivalent. Facture risk and BMD were measured over a 2-year follow-up period. RESULTS: A statistically significant reduction in the risk of fracture was observed at the trochanter in the ZOL group (n = 242) compared with the placebo group (n = 241); (odds ratio 0.54 [95% confidence interval 0.29, 0.98]): BMD was 0.24, 0.28, 0.31 and 0.22 greater at the L1-L4 vertebrae, total hip, femoral neck and trochanter, respectively, in the ZOL group. The incidence of adverse events was comparable between treatment groups. CONCLUSIONS: This study indicated that ZOL could increase BMD and reduce fracture risk in women with osteoporosis over a 2-year follow-up period, and was not associated with any serious drug-related adverse effects.
Entities:
Keywords:
Zoledronic acid; bone mineral density; fracture; osteoporosis; randomized controlled trial
Authors: Rena J Eudy-Byrne; William Gillespie; Matthew M Riggs; Marc R Gastonguay Journal: J Pharmacokinet Pharmacodyn Date: 2017-10-28 Impact factor: 2.745
Authors: Alan I So; Kim N Chi; Brita Danielson; Neil E Fleshner; Anil Kapoor; Tamim Niazi; Frederic Pouliot; Ricardo A Rendon; Bobby Shayegan; Srikala Sridhar; Eric Vigneault; Fred Saad Journal: Can Urol Assoc J Date: 2019-12-05 Impact factor: 1.862
Authors: Sarah Davis; Emma Simpson; Jean Hamilton; Marrissa Martyn-St James; Andrew Rawdin; Ruth Wong; Edward Goka; Neil Gittoes; Peter Selby Journal: Health Technol Assess Date: 2020-06 Impact factor: 4.014